Washington, Sep 1 (AP) President Donald Trump has plastered tariffs on products from almost every country on earth. He's targeted specific imports, including autos, steel and aluminium.

But he isn't done yet.

Trump has promised to impose hefty import taxes on pharmaceuticals, a category of products he's largely spared in his trade war. For decades, in fact, imported medicine has mostly been allowed to enter the United States duty-free.

That's starting to change. US and European leaders recently detailed a trade deal that includes a 15 per cent tariff rate on some European goods brought into the United States, including pharmaceuticals. Trump is threatening duties of 200 per cent more on drugs made elsewhere.

“Shock and awe'' is how Maytee Pereira of the tax and consulting firm PwC describes Trump's plans for drugmakers. “This is an industry that's going from zero (tariffs) to the potential of 200 per cent.'' Trump has promised Americans he'll lower their drug costs. But imposing stiff pharmaceutical tariffs risks the opposite and could disrupt complex supply chains, drive cheap foreign-made generic drugs out of the US market and create shortages.

“A tariff would hurt consumers most of all, as they would feel the inflationary effect ... directly when paying for prescriptions at the pharmacy and indirectly through higher insurance premiums,'' Diederik Stadig, a healthcare economist with the financial services firm ING, wrote in a commentary last month, adding that lower-income households and the elderly would feel the greatest impact.

The threat comes as Trump also pressures drugmakers to lower prices in the United States. He recently sent letters to several companies telling them to develop a plan to start offering so-called most-favoured nation pricing here.

But Trump has said he'd delay the tariffs for a year or a year and a half, giving companies a chance to stockpile medicine and shift manufacturing to the United States - something some have already begun to do.

Leerink Partners analyst David Risinger said in a July 29 note that most drugmakers have already increased drug product imports and may carry between six and 18 months of inventory in the US.

Jefferies analyst David Windley said in a recent research note that tariffs that don't kick in until the back half of 2026 may not be felt until 2027 or 2028 due to stockpiling.

Moreover, many analysts suspect Trump will settle for a tariff far lower than 200 per cent. They are also waiting to see whether any tariff policy includes an exemption for certain products like low-margin generic drugs.

Still, Stadig says, even a 25 per cent levy would gradually raise US drug prices by 10 per cent to 14 per cent as the stockpiles dwindle.

In recent decades, drugmakers have moved many operations overseas - to take advantage of lower costs in China and India and tax breaks in Ireland and Switzerland. As a result, the US trade deficit in medicinal and pharmaceutical products is big -- nearly USD 150 billion last year.

The COVID-19 experience - when countries were desperate to hang onto their own medicine and medical supplies - underscored the dangers of relying on foreign countries in a crisis, especially when a key supplier is America's geopolitical rival, China.

In April, the administration started investigating how importing drugs and pharmaceutical ingredients affects national security. Section 232 of the Trade Expansion Act of 1962 permits the president to order tariffs for the sake of national security.

Marta Wosinska, a health policy analyst at the Brookings Institution, says there is a role for tariffs in securing US medical supplies. The Biden administration, she noted, successfully taxed foreign syringes when cheap Chinese imports threatened to drive US producers out of business.

Trump has bigger ideas: He wants to bring pharmaceutical factories back to the United States, noting that US-made drugs won't face his tariffs.

Drugmakers are already investing in the United States.

The Swiss drugmaker Roche said in April that it will invest USD 50 billion in expanding its US operations. Johnson & Johnson will spend USD 55 billion within the United States in the next four years. CEO Joaquin Duato said recently that the company aims to supply drugs for the US market entirely from sites located there.

But building a pharmaceutical factory in the United States from scratch is expensive and can take several years.

And building in the US wouldn't necessarily protect a drugmaker from Trump's tariffs, not if the taxes applied to imported ingredients used in the medicine. Jacob Jensen, trade policy analyst at the right-leaning American Action Forum, notes that “97 per cent of antibiotics, 92 per cent of antivirals and 83 per cent of the most popular generic drugs contain at least one active ingredient that is manufactured abroad.'' “The only way to truly protect yourself from the tariffs would be to build the supply chain end to end in the United States,'' Pereira said.

Brand-name drug companies have fat profit margins that provide flexibility to make investments and absorb costs as Trump's tariffs begin. Generic drug manufacturers do not.

Some may decide to leave the US market rather than pay tariffs. That could prove disruptive: Generics account for 92 per cent of US retail and mail-order pharmacy prescriptions.

A production pause at a factory in India a couple of years ago led to a chemotherapy shortage that disrupted cancer care. “Those are not very resilient markets,” Brookings' Wosinska said. “If there's a shock, it's hard for them to recover.” She argues that tariffs alone are unlikely to persuade generic drug manufacturers to build US factories: They'd probably need government financing.

“In an ideal world, we would be making everything that's important only in the US,'' Wosinska said. “But it costs a lot of money ... We have offshored so much of our supply chains because we want to have inexpensive drugs. If we want to reverse this, we would really have to redesign our system ... How much are we willing to spend?'' (AP) SKS GSP

Import tariffs on pharmaceuticals could raise domestic drug prices and disrupt supply chains, risking shortages and market exits. The document addresses proposed import tariffs on pharmaceuticals, explaining that authorities may use Section 232 national-security powers to impose duties, with phased implementation to allow stockpiling. It warns tariffs would raise consumer prices, disrupt global supply chains, and disproportionately harm low-margin generic manufacturers, while noting branded firms may better absorb costs and that reshoring production is costly without targeted government support or exemptions.